This is read by an automated voice. Please report any issues or inconsistencies here. Amgen, a Thousand Oaks-based biotechnology giant, has acquired Dark Blue Therapeutics Ltd., a privately held ...

The Toronto Blue Jays seem to love their “short-king catchers.” They have Alejandro Kirk as their roster regular, but have added both Isay Veras and Samuel Orellana via international free agency.

Ask any fashionable woman for her go-to pair of jeans when she wants to look smart, and I can guarantee she’ll point you in the direction of a rich, dark-blue was. Sleeker than lighter washes and ...

The acquisition will enable Amgen to further its research and improve the development of cancer-targeting treatments. US multinational biotechnology company Amgen has announced the acquisition of ...

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 million. The acquisition will strengthen Amgen’s oncology pipeline by ...

Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover of 2026. Through this transaction, Amgen will gain access to Dark Blue’s ...

Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's ...

Amgen has acquired U.K.-based biotechnology company Dark Blue Therapeutics in a transaction valued at up to $840 million. Amgen on Tuesday said the deal adds an investigational small molecule that ...

Amgen's acquisition of Dark Blue Therapeutics focuses on DBT 3757, a promising therapy for AML and ALL, valued at over $840 million. DBT 3757 targets MLLT1/3 proteins, offering potential as a first-in ...